Macaulay V M, Begent R H, Phillips M E, Newlands E S
Cancer Chemother Pharmacol. 1982;9(3):179-81. doi: 10.1007/BF00257749.
Hypomagnesaemia is recognised as a feature of the renal tubular defect produced by cis-platinum therapy for cancer. It may be sufficiently severe to cause tetany and grand mal fits. Attempts to correct established hypomagnesaemia whilst continuing cis-platinum therapy have not proved satisfactory. We have therefore investigated the prophylactic addition of 3 g magnesium sulphate to the high-dose platinum regimen with which metastatic malignant teratoma is treated in this unit. Serum magnesium levels have been measured in eight patients treated in this way and compared with those recorded for eight matched patients previously treated without routine magnesium supplements. Magnesium levels fell into the range frequently associated with clinical manifestation in five of the eight unsupplemented patients and only one of those given magnesium prophylactically. Mean serum magnesium levels were significantly higher in the supplemented group when compared using the paired t-test (P less than 0.01). Routine supplementation with intravenous magnesium sulphate is a simple and effective way of preventing symptomatic hypomagnesaemia associated with cis-platinum therapy.
低镁血症被认为是癌症顺铂治疗所致肾小管缺陷的一个特征。其严重程度可能足以引起手足搐搦和癫痫大发作。在继续进行顺铂治疗的同时试图纠正已有的低镁血症，结果并不令人满意。因此，我们研究了在本单位治疗转移性恶性畸胎瘤所用的高剂量铂类方案中预防性添加3克硫酸镁的情况。已对8例接受这种治疗的患者测定了血清镁水平，并与8例先前未常规补充镁剂的匹配患者的记录水平进行了比较。在8例未补充镁剂的患者中,有5例的镁水平降至常与临床表现相关的范围，而预防性给予镁剂的患者中只有1例出现这种情况。采用配对t检验时，补充组的平均血清镁水平显著较高（P小于0.01）。静脉注射硫酸镁进行常规补充是预防与顺铂治疗相关的症状性低镁血症的一种简单有效的方法。
